Document resource
Background Pancreatic ductal adenocarcinoma (PDAC) remains an indication of immense clinical need. KRAS mutation is a hallmark of most PDAC cases, and several groups are now studying the use of mutant KRAS-selective TCR-modified T-cell therapy (TCR-T). A significant proportion of PDAC patients benefit from initial standard-of-care (SOC) chemotherapy, but progress later due to chemotherapy resistance. We hypothesize that PDAC patients with at least stable disease after SOC first-line chemotherapy will have a therapeutic benefit from additional TCR-T.A highly potent TCR specific for KRAS G12V restricted by A*11:01 has been developed1 and is available for autologous TCR-T via an approved GMP process incorporating gene-editing and recovery of purified CD8+ TCR+ TCR-T cells. This TCR-T product is designated ANOC-001Methods Registration : EUCT 2024-513900-32-00Study Design: Phase I/IIa, open-label, multicentre studyIntervention: SOC followed by low-dose lymphodepletion and single infusion of ANOC-001Patient Population: Adult subjects with locally advanced or metastatic PDAC, with disease control after c.16 weeks of SOCThe ANOC-001 sub-study of VIDAR-1 is opening at eight centres in the EU. Adult HLA- and mutation-matched PDAC patients with newly diagnosed metastatic or locally advanced non-resectable disease are eligible. The phase 1 part follows a 3+3 dose escalation design with two dose levels to determine safety and tolerability of ANOC-001 and establish the recommended phase 2 dose (RP2D). In a phase 2a extension part up to 20 patients will be treated at the RP2D to preliminarily assess the anti-tumour activity of ANOC-001. Leukapheresis to collect autologous T-cell inputs for ANOC-001 manufacturing takes place before or within early cycles of SOCTrial Registration EUCT 2024-513900-32-00Reference Salter, et al. Preclinical development of TCR-modified T cell therapies against mutated KRAS. Annals Oncol. 2024;35:S694-S694.Ethics Approval At country-level obtained during CTIS part II evaluation of EUCT 2024-513900-32-00.